Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Tocilizumab Fails Late-Stage Trial for COVID-19

John Revill  |  

In the COVACTA trial, there was no difference in mortality rates after four weeks between patients who took tocilizumab and those who did not.

“People around the world are waiting for further effective treatment options for COVID-19 and we are disappointed that COVACTA did not demonstrate a benefit for patients in either clinical status or mortality at week four,” Levi Garraway, Roche’s chief medical officer, says.

ADVERTISEMENT
SCROLL TO CONTINUE

 

Related Articles

    FDA Provides 2020 Rheumatology Drug Update

    Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

    Tocilizumab Fails to Help COVID-19 Patients in Italian Study

    (Reuters)—Roche’s rheumatoid arthritis drug Actemra (tocilizumab) failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial. Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing tocilizumab in another trial against COVID-19, the disease…

    Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

    (Reuters)—A key U.S. government trial of Gilead Sciences Inc.’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study. Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy…